Current perspectives in assessment of fetal pulmonary surfactant status with amniotic fluid.
In recent years, improvements in analytical methodology and clinical management of maternal-fetal diseases have altered the understanding of data from amniotic fluid analysis. Delays in phospholipid production or lung function are not currently reported in maternal diabetes. Fetal lung function following glucocorticoid therapy or premature membrane rupture is uncoupled from amniotic fluid phospholipid concentrations, which do not have the usual significance in these circumstances. Phosphatidylglycerol (PG) is present prior to the usual time it is detected by thin layer chromatography (TLC) methods, which vary in sensitivity for PG. Consequently, the significance of its "absence" is highly varied. These observations are discussed in light of the earlier methods and data, along with new perceptions of the functions of the individual phospholipids and apoproteins, the regulatory mechanism of surfactant production, and the relationship of amniotic fluid components to neonatal lung function.